|

Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Second Affiliated Hospital of Guangzhou Medical University1

Indications

  • CAR NK1
  • Testis Cancer, Refractory1
  • Endometrial Cancer Recurrent1
  • Stage IV Ovarian Cancer1
  • Cancer1

Other1 trial

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.